A Randomised, Double-blind, Placebo-controlled and Parallel Group Trial to Evaluate Efficacy and Safety of Twice Daily Inhaled Doses of BI 1265162 Delivered by Respimat® Inhaler as add-on Therapy to Standard of Care Over 4 Weeks in Patients With Cystic Fibrosis - BALANCE - CF™ 1
收藏DataCite Commons2025-05-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007551/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of this trial is to assess the efficacy, safety and pharmacokinetics of
twice daily inhaled doses of BI 1265162 delivered by Respimat® inhaler versus placebo in
adolescents and adult patients with cystic fibrosis.
提供机构：
Vivli
创建时间：
2021-12-17
